Form 4: Intellia CFO Sells Shares for Tax Obligation

Intellia Therapeutics' EVP and CFO, Edward J. Dulac III, sold 6,379 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Edward J. Dulac III, Executive Vice President and Chief Financial Officer of Intellia Therapeutics, Inc. (NTLA), reported a transaction involving the company's common stock.
• On January 5, 2026, Mr. Dulac disposed of 6,379 shares of common stock at a price of $9.21 per share.
• This transaction was a mandatory 'sell-to-cover' to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) on January 1, 2026.
• The sale was not a volitional trade by Mr. Dulac.
• Following this transaction, Mr. Dulac beneficially owns 99,683 shares of Intellia Therapeutics common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a mandatory 'sell-to-cover' for tax purposes, not a discretionary sale indicating a change in management's outlook on the company.

Future Outlook

NA

Management Comments

• The transaction represents a mandatory 'sell-to-cover' for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person.

Industry Context

This filing details a routine insider transaction for tax purposes and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: The sale is a routine, non-volitional transaction for tax purposes and is unlikely to significantly impact shareholder sentiment or the company's strategic direction.

Key Dates

Keywords

Intellia Therapeutics, NTLA, Form 4, Insider Transaction, Stock Sale, CFO, Restricted Stock Units, Tax Withholding